Join

Compare · EFTR vs JNJ

EFTR vs JNJ

Side-by-side comparison of eFFECTOR Therapeutics Inc. (EFTR) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both EFTR and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • JNJ is the larger of the two at $537.39B, about 2341.8x EFTR ($229.5M).
  • Over the past year, EFTR is up 0.0% and JNJ is up 45.9% - JNJ leads by 45.9 points.
  • JNJ has hit the wire 12 times in the past 4 weeks while EFTR has been quiet.
  • JNJ has more recent analyst coverage (25 ratings vs 9 for EFTR).
PerformanceEFTR+0.00%JNJ+0.52%
2025-06-04+0.00%2025-07-01
MetricEFTRJNJ
Company
eFFECTOR Therapeutics Inc.
Johnson & Johnson
Price
$0.19-26.76%
$223.61+0.31%
Market cap
$229.5M
$537.39B
1M return
+0.00%
-0.24%
1Y return
+0.00%
+45.93%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
12
Recent ratings
9
25
EFTR

eFFECTOR Therapeutics Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

JNJ

Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Latest EFTR

Latest JNJ